Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2012

01-12-2012 | Editorial

Anaplastic thyroid cancer therapy: dream or reality?

Author: Rossella Elisei

Published in: Endocrine | Issue 3/2012

Login to get access

Excerpt

Anaplastic thyroid cancer (ATC) is a rare thyroid malignancy representing 2 % of thyroid tumors. Usually, ATC is a lethal tumor with an overall median survival time <6 months from the diagnosis. Anecdotic cases of long-term survivors have been reported mainly in subjects with intrathyroid tumors at the time of surgical treatment [1]. …
Literature
1.
S.M. Lim, S.J. Shin, W.Y. Chung, C.S. Park, K.H. Nam, S.W. Kang, K.C. Keum, J.H. Kim, J.Y. Cho, Y.K. Hong, B.C. Cho, Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. Yonsei Med. J. 53(2), 352–357 (2012)PubMedCrossRef
2.
A. Wunderlich, S. Roth, A. Ramaswamy, B.H. Greene, C. Brendel, U. Hinterseher, D.K. Bartsch, S. Hoffmann, Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer. Endocrine (2012). doi:10.​1007/​s12020-012-9665-4
3.
A. Wunderlich, T. Arndt, M. Fischer, S. Roth, A. Ramaswamy, B.H. Greene, C. Brendel, U. Hinterseher, D.K. Bartsch, S. Hoffmann, Targeting the proteasome as a promising therapeutic strategy in thyroid cancer. J. Surg. Oncol. 105(4), 357–364 (2012)PubMedCrossRef
4.
Y. Arlot-Bonnemains, E. Baldini, B. Martin, J.G. Delcros, M. Toller, F. Curcio, F.S. Ambesi-Impiombato, M. D’Armiento, S. Ulisse, Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Endocr. Relat. Cancer 15(2), 559–568 (2008)PubMedCrossRef
5.
S. Libertini, A. Abagnale, C. Passaro, G. Botta, S. Barbato, P. Chieffi, G. Portella, AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947. Endocr. Relat. Cancer 18(1), 129–141 (2011)PubMedCrossRef
6.
A. Antonelli, G. Bocci, C. La Motta, S.M. Ferrari, P. Fallahi, I. Ruffilli, A. Di Domenicantonio, A. Fioravanti, S. Sartini, M. Minuto, S. Piaggi, A. Corti, G. Ali, T. Di Desidero, P. Berti, G. Fontanini, R. Danesi, F. Da Settimo, P. Miccoli, CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J. Clin. Endocrinol. Metab. 97(4), E528–E536 (2012)PubMedCrossRef
7.
W.B. Zhong, S.P. Hsu, P.Y. Ho, Y.C. Liang, T.C. Chang, W.S. Lee, Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the Rho/ROCK-mediated pathway. Biochem. Pharmacol. 82(11), 1663–1672 (2011)PubMedCrossRef
8.
S. Gholami, D. Haddad, C.H. Chen, N.G. Chen, Q. Zhang, P.B. Zanzonico, A.A. Szalay, Y. Fong, Novel therapy for anaplastic thyroid carcinoma cells using an oncolytic vaccinia virus carrying the human sodium iodide symporter. Surgery 150(6), 1040–1047 (2011)PubMedCrossRef
9.
R. Elisei, A. Vivaldi, R. Ciampi, P. Faviana, F. Basolo, F. Santini, C. Traino, F. Pacini, A. Pinchera, Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. J. Clin. Endocrinol. Metab. 91(6), 2389–2395 (2006)PubMedCrossRef
10.
R. Elisei, J. Sosa, B. Jarzab et al., Randomized phase 2/3 trial of a tumor vascular disrupting agent fosbretabulin (CA4P) with carboplatin and paclitaxel in anaplastic thyroid cancer (ATC). ITC Abstract Book (2010)
11.
V. Gupta-Abramson, A.B. Troxel, A. Nellore, K. Puttaswamy, M. Redlinger, K. Ransone, S.J. Mandel, K.T. Flaherty, L.A. Loevner, P.J. O’Dwyer, M.S. Brose, Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol. 26(29), 4714–4719 (2008)PubMedCrossRef
Metadata
Title
Anaplastic thyroid cancer therapy: dream or reality?
Author
Rossella Elisei
Publication date
01-12-2012
Publisher
Springer US
Published in
Endocrine / Issue 3/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9785-x

Other articles of this Issue 3/2012

Endocrine 3/2012 Go to the issue

Letter to the Editor

The effect of oral presentation on salivary 3-methoxy-4-hydroxy-phenylglycol (MHPG) and cortisol concentrations in training doctors: a preliminary study

Letter to the Editor

Metformin and human uterine contractility

Original Article

Diagnostic value of antithyroid peroxidase antibody for incidental autoimmune thyroiditis based on histopathologic results

Endocrine Imaging

Gangrene from finger pricking

Erratum

Erratum to: Elevated A1C is associated with impaired early-phase insulin secretion rather than insulin resistance in Koreans at high risk for developing diabetes

Original Article

Insulin resistance and acne: a new risk factor for men?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits